NASDAQ:CMRXChimerix Stock Price, Forecast & News

Chimerix's stock was trading at $1.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 129.2% and is now trading at $3.30. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chimerix.

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chimerix.

Chimerix Inc (NASDAQ:CMRX) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analyst estimates of $1.50 million. Chimerix had a negative net margin of 923.87% and a negative return on equity of 34.16%. View Chimerix's earnings history.

1 Wall Street analysts have issued twelve-month price targets for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Chimerix's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 112.1% from the stock's current price. View analysts' price targets for Chimerix.

Media coverage about CMRX stock has trended extremely negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chimerix earned a daily sentiment score of -4.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutChimerix.

Chimerix saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,440,000 shares, an increase of 5.9% from the April 30th total of 1,360,000 shares. Based on an average daily volume of 960,900 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.2% of the shares of the stock are short sold. View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Arcturus Therapeutics (ARCT), Kura Oncology (KURA), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), Kala Pharmaceuticals (KALA), Dynavax Technologies (DVAX), Kadmon (KDMN), Collegium Pharmaceutical (COLL), Akero Therapeutics (AKRO), Molecular Templates (MTEM), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Homology Medicines (FIXX), G1 Therapeutics (GTHX) and Provention Bio (PRVB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), SLS International (SLS), Wynn Resorts (WYNN), Gilead Sciences (GILD), Opko Health (OPK) and Sorrento Therapeutics (SRNE).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.40%), State Street Corp (2.01%), Acadian Asset Management LLC (1.57%), Geode Capital Management LLC (1.48%), Nuveen Asset Management LLC (1.25%) and Two Sigma Advisers LP (1.10%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View institutional ownership trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, UBS Group AG, Two Sigma Advisers LP, Morgan Stanley, Connor Clark & Lunn Investment Management Ltd., and Squarepoint Ops LLC. View insider buying and selling activity for Chimerix.

CMRX stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., Marquette Asset Management LLC, Ikarian Capital LLC, GSA Capital Partners LLP, and Geode Capital Management LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer. View insider buying and selling activity for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $3.30.

Chimerix has a market capitalization of $204.37 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

The official website for Chimerix is www.chimerix.com.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]